Clinical Trial: Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) o

Brief Summary: An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

Detailed Summary:
Sponsor: UCB Pharma

Current Primary Outcome: Reduction in neuroleptic-induced tardive dyskinesia over an 8 week treatment period

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Neuroleptic-induced akathisia and other extrapyramidal symptoms ,
  • Effect on the primary psychiatric disorder
  • Safety


Original Secondary Outcome: Same as current

Information By: UCB Pharma

Dates:
Date Received: September 9, 2005
Date Started: May 2005
Date Completion:
Last Updated: December 5, 2013
Last Verified: September 2009